Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAX06Q
|
|||
| Drug Name |
AMG 509
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metalloreductase STEAP1 (STEAP1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Mineral absorption | |||
| WikiPathways | Copper homeostasis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04221542) Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.